All In Biotech

Drug Trial Radar · NCT05468450

RCT Comparing EVLA Versus Polidocanol Foam in the Treatment of SSV Insufficiency

Three-year Outcomes of a RCT Comparing EVLA Versus Polidocanol Foam in the Treatment of SSV Insufficiency (FOVELASS Study, by the French Society of Phlebology)

Last checked: Nov 20, 2026Latest source record: Jul 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 161 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

161

Actual

Start

Jul 1, 2015

Primary completion

Aug 31, 2016

Study completion Aug 31, 2016

Sponsor

Lead sponsor
Societe Francaise de PhlebologieAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

FOVELASS is a multicentre-RCT (11 centres) comparing ultrasound-guided-foam sclerotherapy (UGFS) and Endovenous Laser Ablation (EVLA) for treating SSV insufficiency, conducted by the French Society of Phlebology.

Conditions

  • Varicose Veins of Lower Limb

Interventions

  • Ultrasound-guided-foam sclerotherapy (UGFS) using Polidocanol sclerosantDrug

    Direct injection Foam sclerotherapy

  • Endovenous Laser Ablation (EVLA)Device

    EVLA using a 1470nm generator and 600-micron radial fibres (Biolitec® Biomedical Technology, Jena, Germany), under tumescent local anaesthesia (TLA)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absence of reflux in the treated SSV segmentTime frame: 3Assessed at years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.